RxDoctor Payments Data

Dimitri Sherev, MD

Interventional Cardiology · El Cajon, CANPI 1154323996

Payments from drug & device makers

$173,360in general payments, 2019–2025

Across 1,407 payments — averaging $123.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$110K
  • Edwards Lifesciences$34K
  • Abbott$4K
  • Medtronic$4K
  • Boston Scientific$2K
  • Novartis$2K
  • plus $18K from 54 others

What the payments were for

  • Consulting fees$27,47043%
  • Travel & lodging$2,7654%
  • Food & beverage$33,06052%
  • Education$950%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
CSL Behring95$109,970
Edwards Lifesciences83$33,707
Abbott121$4,016
Medtronic(3 entities)113$3,939
Boston Scientific87$1,883
Novartis86$1,550
Abiomed46$1,304
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)60$1,187
Cvrx, Inc.43$1,018
Johnson & Johnson54$1,009
Philips North America LLC31$923
Actelion Pharmaceuticals US, Inc.74$920
Amgen46$889
Merck31$746
Bayer33$701
AstraZeneca38$666
Biotronik Inc.17$603
Pfizer30$585
Boehringer Ingelheim24$572
E.r. Squibb & Sons, L.L.C.26$443
Heartflow, Inc.8$426
Shockwave Medical, Inc2$424
Sanofi-aventis U.S. LLC21$357
Endologix LLC2$308
Braemar Manufacturing, LLC1$306
Esperion Therapeutics, Inc.20$285
Novo Nordisk12$253
Amarin Pharma, Inc.12$241
Bard Peripheral Vascular, Inc.8$234
Cardiva Medical, Inc.12$233
Regeneron Healthcare Solutions, Inc.11$226
Impulse Dynamics (USA) Inc.8$219
Alnylam Pharmaceuticals Inc.11$210
Reflow Medical Inc7$187
Cordis US CORP.5$183
Kestra Medical Technology Services, Inc.4$172
Inari Medical, Inc.8$168
Irhythm Technologies, Inc.4$163
Kiniksa Pharmaceuticals, Ltd.9$157
Daiichi Sankyo Inc.16$149
Angiodynamics, Inc.6$145
Cardiovascular Systems Inc.9$137
Cardinal Health 200 LLC6$137
Kiniksa Pharmaceuticals International, PLC7$133
Amryt Pharma Holdings Ltd4$87
Lexicon Pharmaceuticals, Inc.4$86
Gilead3$86
Akcea Therapeutics, Inc.3$85
Scpharmaceuticals Inc.3$78
Cathworks, Inc.1$73
Penumbra, Inc.4$70
Chiesi USA, Inc.4$60
Tactile Systems Technology Inc3$53
Lilly USA, LLC2$50
Kowa Pharmaceuticals America, Inc.2$48
Bristol Myers Squibb2$45
Bardy Diagnostics, Inc.3$45
Imperative Care, Inc2$43
Getinge USA Sales, LLC1$27
Acutus Medical, Inc.1$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$173,360 in reported general payments places this provider in the 85th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$1,567,803
Medicare patients
1,257
Services billed
11,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban637$701,381
EntrestoSacubitril/Valsartan202$204,499
XareltoRivaroxaban138$164,370
Repatha SureclickEvolocumab116$86,940
FarxigaDapagliflozin Propanediol97$78,412
OzempicSemaglutide76$76,674
BrilintaTicagrelor119$69,458
JardianceEmpagliflozin52$52,680
Repatha SyringeEvolocumab37$32,366
KerendiaFinerenone30$29,164
NexlizetBempedoic Acid/Ezetimibe43$22,324
VascepaIcosapent Ethyl51$19,658
WegovySemaglutide11$14,261
Praluent PenAlirocumab19$13,739
NexletolBempedoic Acid26$13,463

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$585$701,381637 claims
NovartisEntresto$1,550$204,499202 claims
Johnson & JohnsonXarelto$1,009$164,370138 claims
AstraZenecaFarxiga, Brilinta$666$147,869216 claims
Novo NordiskOzempic, Wegovy$253$90,93587 claims
Boehringer IngelheimJardiance, Tradjenta$572$58,87664 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$285$35,78669 claims
BayerKerendia$701$29,16430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in El Cajon

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →